{"id":"imipenem-and-cilastatin-sodium","safety":{"commonSideEffects":[{"rate":"1-2%","effect":"Nausea"},{"rate":"1-2%","effect":"Diarrhea"},{"rate":"0.5-1%","effect":"Vomiting"},{"rate":"3-5%","effect":"Phlebitis at injection site"},{"rate":"0.5-1%","effect":"Seizures"},{"rate":"1-3%","effect":"Hypersensitivity reactions"},{"rate":"1-2%","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1201057","moleculeType":"Small molecule","molecularWeight":"380.44"},"_dailymed":{"setId":"f41d8abd-7792-4918-1b93-bd83ea01955e","title":"PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imipenem is a broad-spectrum beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Cilastatin sodium is a dehydropeptidase inhibitor that protects imipenem from renal metabolism, allowing higher urinary concentrations and reducing nephrotoxicity while maintaining systemic antibiotic efficacy.","oneSentence":"Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while cilastatin prevents imipenem degradation by inhibiting renal dehydropeptidase I.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:58.412Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, and septicemia"},{"name":"Polymicrobial infections and infections caused by gram-positive and gram-negative aerobic and anaerobic bacteria"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06059846","phase":"PHASE3","title":"A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2023-12-21","conditions":"Urinary Tract Infection, Acute Pyelonephritis","enrollment":1690},{"nctId":"NCT03969901","phase":"PHASE2, PHASE3","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Suspected or Documented Gram-negative Bacterial Infection","enrollment":115},{"nctId":"NCT07361198","phase":"NA","title":"Percutaneous Transcatheter Genicular Embolization in Osteoarthritis","status":"RECRUITING","sponsor":"Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.","startDate":"2026-02-02","conditions":"Osteoarthritic Knee Pain, Osteo Arthritis of the Knee, Osteoarthitis","enrollment":20},{"nctId":"NCT05887908","phase":"PHASE3","title":"Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2023-05-23","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis, cUTI","enrollment":614},{"nctId":"NCT06929585","phase":"NA","title":"Genicular Artery Embolization (GAE) vs inTra-articular Corticosteroid Injection for Osteoarthritic Knee Pain.","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2025-03-25","conditions":"Osteoarthritis (OA) of the Knee","enrollment":1},{"nctId":"NCT05204563","phase":"PHASE3","title":"Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)","status":"COMPLETED","sponsor":"Evopoint Biosciences Inc.","startDate":"2022-07-31","conditions":"Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia","enrollment":450},{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia","enrollment":274},{"nctId":"NCT06569056","phase":"PHASE3","title":"A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-09-25","conditions":"Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)","enrollment":578},{"nctId":"NCT05561764","phase":"PHASE4","title":"Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis","status":"TERMINATED","sponsor":"Hartford Hospital","startDate":"2023-01-03","conditions":"Cystic Fibrosis, Pneumonia, Bacterial","enrollment":4},{"nctId":"NCT05146154","phase":"PHASE4","title":"Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients","status":"WITHDRAWN","sponsor":"University of Illinois at Chicago","startDate":"2023-01-01","conditions":"Obesity, Critical Illness","enrollment":""},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT04785924","phase":"PHASE4","title":"Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2021-06-07","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections","enrollment":""},{"nctId":"NCT04493151","phase":"PHASE1","title":"Imipenem/Cilastatin/Relebactam PK in ECMO","status":"COMPLETED","sponsor":"Joseph L. Kuti, PharmD","startDate":"2021-01-01","conditions":"Sepsis","enrollment":8},{"nctId":"NCT04147221","phase":"PHASE1","title":"Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2020-02-10","conditions":"Sepsis","enrollment":9},{"nctId":"NCT03230916","phase":"PHASE1","title":"A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-06","conditions":"Suspected or Documented Gram-negative Bacterial Infection","enrollment":47},{"nctId":"NCT06144060","phase":"PHASE2","title":"A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-12","conditions":"Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)","enrollment":126},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05930639","phase":"NA","title":"The Effect of the Care Bundle to be Applied to Obesity Surgery Patients on Surgical Site Infection and Patient Comfort","status":"UNKNOWN","sponsor":"Malatya Turgut Ozal University","startDate":"2023-06-12","conditions":"Bariatric Surgery Candidate","enrollment":70},{"nctId":"NCT05204368","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)","status":"UNKNOWN","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-03-30","conditions":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","enrollment":780},{"nctId":"NCT04482569","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin","status":"COMPLETED","sponsor":"Evopoint Biosciences Inc.","startDate":"2020-07-10","conditions":"Bacterial Infections","enrollment":88},{"nctId":"NCT04787562","phase":"PHASE1","title":"Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function","status":"COMPLETED","sponsor":"Evopoint Biosciences Inc.","startDate":"2021-02-25","conditions":"Bacterial Infections","enrollment":39},{"nctId":"NCT04801043","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.","status":"COMPLETED","sponsor":"Evopoint Biosciences Inc.","startDate":"2021-03-02","conditions":"Bacterial Infections","enrollment":24},{"nctId":"NCT04802863","phase":"PHASE1","title":"Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Evopoint Biosciences Inc.","startDate":"2021-03-25","conditions":"Bacterial Infections","enrollment":21},{"nctId":"NCT03894046","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","status":"COMPLETED","sponsor":"Entasis Therapeutics","startDate":"2019-09-05","conditions":"Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":207},{"nctId":"NCT03177720","phase":"PHASE1","title":"Evaluation of Innovative Tools in Development of Antibiotics","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2016-05-29","conditions":"Pneumonia","enrollment":10},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04764058","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Colistin Based Antibiotic Therapy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-09-01","conditions":"Septicemia, Bacterial Infections","enrollment":60},{"nctId":"NCT03293485","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-04","conditions":"Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection","enrollment":83},{"nctId":"NCT01275170","phase":"PHASE1","title":"A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-28","conditions":"Infectious Disease","enrollment":49},{"nctId":"NCT02533609","phase":"","title":"Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis","status":"UNKNOWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2015-09","conditions":"Acute Kidney Injury, Bacterial Infection","enrollment":30},{"nctId":"NCT02611271","phase":"","title":"Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy","status":"UNKNOWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2017-12-01","conditions":"Critical Illness, Sepsis, Acute Kidney Injury","enrollment":30},{"nctId":"NCT03858387","phase":"","title":"PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients","status":"UNKNOWN","sponsor":"Prince of Songkla University","startDate":"2018-09-01","conditions":"Critical Illness, Bacterial Infections","enrollment":102},{"nctId":"NCT02493764","phase":"PHASE3","title":"Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-24","conditions":"Bacterial Pneumonia","enrollment":537},{"nctId":"NCT03445195","phase":"PHASE2","title":"Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Entasis Therapeutics","startDate":"2018-01-17","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":80},{"nctId":"NCT02321800","phase":"PHASE2","title":"A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Shionogi","startDate":"2015-02-05","conditions":"Urinary Tract Infections","enrollment":452},{"nctId":"NCT04196608","phase":"","title":"In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients","status":"UNKNOWN","sponsor":"Emilio Bouza","startDate":"2019-11-01","conditions":"Ceftolozane/Tazobactam, Imipenem/Relebactam, Hematology and Oncology","enrollment":1005},{"nctId":"NCT02149329","phase":"PHASE4","title":"Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-12","conditions":"Febrile Neutropenia, Hematological Malignancy","enrollment":276},{"nctId":"NCT01506271","phase":"PHASE2","title":"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-01","conditions":"Intra-abdominal Infections","enrollment":351},{"nctId":"NCT01505634","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-16","conditions":"Urinary Tract Infections, Pyelonephritis","enrollment":302},{"nctId":"NCT00515034","phase":"PHASE2","title":"A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-10","conditions":"Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia","enrollment":146},{"nctId":"NCT03159078","phase":"PHASE3","title":"Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens","status":"UNKNOWN","sponsor":"University of Puerto Rico","startDate":"2017-05-25","conditions":"Trauma, Resistant Infection, Critical Illness","enrollment":40},{"nctId":"NCT02452047","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-21","conditions":"Bacterial Infections","enrollment":50},{"nctId":"NCT01721408","phase":"PHASE4","title":"A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Intra-abdominal Infection","enrollment":470},{"nctId":"NCT01381549","phase":"PHASE2","title":"GSK2251052 in Complicated Urinary Tract Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-06-28","conditions":"Infections, Urinary Tract","enrollment":20},{"nctId":"NCT00619710","phase":"PHASE3","title":"Complicated Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-02","conditions":"Skin Infection, Abscess, Cellulitis","enrollment":1000},{"nctId":"NCT02897206","phase":"PHASE4","title":"Imipenem Prophylaxis in Patients With Acute Pancreatitis","status":"COMPLETED","sponsor":"University Hospital Rijeka","startDate":"2014-10","conditions":"Acute Pancreatitis","enrollment":98},{"nctId":"NCT02971423","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects","status":"COMPLETED","sponsor":"Entasis Therapeutics","startDate":"2016-10","conditions":"Acinetobacter Baumannii Infection","enrollment":124},{"nctId":"NCT00445094","phase":"PHASE4","title":"A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Infection, Pneumonia","enrollment":120},{"nctId":"NCT01797133","phase":"NA","title":"A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2013-02","conditions":"All Hospitalzied Patients, No Specific Conditions Requires","enrollment":984},{"nctId":"NCT02616354","phase":"PHASE4","title":"Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin","status":"UNKNOWN","sponsor":"Southeast University, China","startDate":"2015-01","conditions":"Sepsis","enrollment":24},{"nctId":"NCT01820026","phase":"PHASE4","title":"Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-12","conditions":"Cirrhosis","enrollment":96},{"nctId":"NCT02213783","phase":"PHASE4","title":"Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2011-02","conditions":"Patients With Febrile Neutropenia","enrollment":12},{"nctId":"NCT02191475","phase":"PHASE2, PHASE3","title":"Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-05","conditions":"Abdominal Infection","enrollment":100},{"nctId":"NCT00081744","phase":"PHASE3","title":"Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-11","conditions":"Gram-Positive Bacterial Infections, Cross Infection","enrollment":850},{"nctId":"NCT00589693","phase":"PHASE3","title":"To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-04","conditions":"Ventilator-Associated Pneumonia","enrollment":274},{"nctId":"NCT00707239","phase":"PHASE2","title":"Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Pneumonia, Bacterial","enrollment":108},{"nctId":"NCT01297842","phase":"PHASE4","title":"Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2011-05","conditions":"Drug Safety","enrollment":100},{"nctId":"NCT00236834","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-12","conditions":"Nosocomial Pneumonia","enrollment":438},{"nctId":"NCT01356472","phase":"PHASE4","title":"Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2011-06","conditions":"Methicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated","enrollment":60},{"nctId":"NCT00136201","phase":"PHASE3","title":"Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-11","conditions":"Abdominal Abscess","enrollment":200},{"nctId":"NCT00080496","phase":"PHASE3","title":"Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2003-07","conditions":"Bacterial Pneumonia","enrollment":430}],"_emaApprovals":[],"_faersSignals":[{"count":25,"reaction":"PNEUMONIA"},{"count":25,"reaction":"PYREXIA"},{"count":22,"reaction":"OFF LABEL USE"},{"count":21,"reaction":"DIARRHOEA"},{"count":20,"reaction":"PLATELET COUNT DECREASED"},{"count":19,"reaction":"ANAEMIA"},{"count":18,"reaction":"SEPTIC SHOCK"},{"count":18,"reaction":"THROMBOCYTOPENIA"},{"count":15,"reaction":"RASH"},{"count":15,"reaction":"RESPIRATORY FAILURE"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Imipenem and Cilastatin Sodium","genericName":"Imipenem and Cilastatin Sodium","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while cilastatin prevents imipenem degradation by inhibiting renal dehydropeptidase I. Used for Serious bacterial infections including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, and septicemia, Polymicrobial infections and infections caused by gram-positive and gram-negative aerobic and anaerobic bacteria.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}